In Western markets, pharmaceutical companies have developed many approaches to patient access programs (PAPs), normally emphasizing initiatives that, while helping patients, also support pricing and reimbursement initiatives, such as: Early access programs before market authorization. Financial…
In today’s competitive global market, pharmaceutical companies can’t afford to waste time or resources on strategies that don’t generate scripts or fit product and patient needs. Without data-informed, fully integrated campaigns, there’s a missed opportunity to…
As pharma continues to evolve, commercialization models must evolve also. In this PharmaVOICE webinar, EVERSANA’s Rohit Sood, EVP, COMPLETE Commercialization, and Resverlogix’s CEO Donald J. McCaffrey discuss why pharma companies are focusing on new commercial models…
The following opinion piece was written by Scott Snyder, Chief Digital Officer, for Knowledge@Wharton. Outsider attempts to reinvent healthcare have done little to move the needle despite billions invested in promising concepts like Microsoft’s HealthVault, IBM’s…
Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the…
“Drugs don’t work in patients who don’t take them.” − Former U.S. Surgeon General C. Everett Coop While it seems obvious, the amount of attention given to adherence is extremely low, especially in comparison to the high costs associated with non-adherence.…
Kevin O’Meara, EVERSANA’s Vice President of Patient Services Solutions, joined Peter Avalos, National Reimbursement Director at Daiichi Sankyo, Inc., to discuss the current challenges impeding patient access and how to best optimize your co-pay programs using customized solutions and digital innovations.
In our last update, we discussed the proposed rule that the Centers for Medicare and Medicaid Services (CMS) issued regarding the addition of certain Current Procedural Terminology (CPT®) codes to identify remote therapeutic monitoring (RTM) in…
The Centers for Medicare and Medicaid Services (CMS) released the proposed Medicare physician fee schedule regulation for 2022, which includes an analysis and payment calculations for the new Remote Therapeutic Monitoring (RTM) CPT codes issued by…
In Medicare’s drive to improve outcomes of the fee-for-service (FFS) payment model, this model is being replaced with value-based care. The delivery of value-based care is not supported by FFS payments, which incentivize the volume of…